Probe-dependent negative allosteric modulators of the long-chain free fatty acid receptor FFA4

Molecular Pharmacology

Volumn 91, Issue 6, 2017, Pages 630-641

  Watterson, Kenneth R ^a   Hansen, Steffen V F ^b   Hudson, Brian D ^a   Alvarez Curto, Elisa ^a   Raihan, Sheikh Zahir ^a   Azevedo, Carlos M G ^b   Martin, Gabriel ^b   Dunlop, Julia ^a   Yarwood, Stephen J ^a,c   Ulven, Trond ^b   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYL N (9H XANTHEN 9 YL)BENZAMIDE; 4 METHYL N 9H XANTHEN 9 YL BENZENESULFONAMIDE; BENZENESULFONAMIDE DERIVATIVE; FREE FATTY ACID RECEPTOR 4; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 40; INOSITOL PHOSPHATE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; XANTHENE DERIVATIVE; 3-(4-((4-FLUORO-4'-METHYL-(1,1'-BIPHENYL)-2-YL)METHOXY)PHENYL)PROPANOIC ACID; BIPHENYL DERIVATIVE; O3FAR1 PROTEIN, HUMAN; PHENYLPROPIONIC ACID DERIVATIVE;

ADIPOCYTE; ALLOSTERISM; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C3H MOUSE; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; PHYSIOLOGY; TUMOR CELL LINE;

ALLOSTERIC REGULATION; ANIMALS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; MICE, INBRED C3H; PHENYLPROPIONATES; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85019459693     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.116.107821     Document Type: Article

References (50)

1. Alvarez-Curto E, Inoue A, Jenkins L, Raihan SZ, Prihandoko R, Tobin AB, and Milligan G (2016) Targeted elimination of G proteins and arrestins defines their specific contributions to both intensity and duration of G protein-coupled receptor signaling. J Biol Chem291: 27147-27159.
2. Azevedo CM, Watterson KR, Wargent ET, Hansen SV, Hudson BD, Kȩpczýnska MA, Dunlop J, Shimpukade B, Christiansen E, Milligan G, et al. (2016) Non-acidic free fatty acid receptor 4 agonists with antidiabetic activity. J Med Chem 59: 8868-8878.
3. Butcher AJ, Hudson BD, Shimpukade B, Alvarez-Curto E, Prihandoko R, Ulven T, Milligan G, and Tobin AB (2014) Concomitant action of structural elements and receptor phosphorylation determines arrestin-3 interaction with the free fatty acid receptor FFA4. J Biol Chem 289:18451-18465.
4. Charlton SJ and Vauquelin G (2010) Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br J Pharmacol 161: 1250-1265.
5. Chelliah M, Chu HD, Cox JM, Debenham JS, Eagen K, Lan P, London C, Plotkin MA, Shah U, Sinz CJ et al. (2014) Merck Sharp & Dohme Corporation, assignee. Preparation of substituted spiropiperidinyl compounds useful as GPR120 agonists. WO2014059232A2.
6. Christiansen E, Hansen SV, Urban C, Hudson BD, Wargent ET, Grundmann M, Jenkins L, Zaibi M, Stocker CJ, Ullrich S, et al. (2013) Discovery of TUG-770: A highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. ACS Med Chem Lett 4:441-445.
7. Christiansen E, Watterson KR, Stocker CJ, Sokol E, Jenkins L, Simon K, Grundmann M, Petersen RK,Wargent ET, Hudson BD, et al. (2015) Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. Br J Nutr 113:1677-1688.
8. Cornall LM, Mathai ML, Hryciw DH, and McAinch AJ (2014) GPR120 agonism as a countermeasure against metabolic diseases. Drug Discov Today 19:670-679.
9. Cozzi PG and Zoli L (2008) A rational approach towards the nucleophilic substitutions of alcohols "on water". Angew Chem Int Ed Engl 47:4162-4166.
10. Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev 65: 967-986.
11. Gao B, Huang Q, Jie Q, Lu WG, Wang L, Li XJ, Sun Z, Hu YQ, Chen L, Liu BH, et al. (2015) GPR120: A bi-potential mediator to modulate the osteogenic and adipogenic differentiation of BMMSCs. Sci Rep 5:14080.
12. Ghislain J and Poitout V (2017) The role and future of FFA1 as a therapeutic target. Handb Exp Pharmacol 236:159-180.
13. Gotoh C, Hong YH, Iga T, Hishikawa D, Suzuki Y, Song SH, Choi KC, Adachi T, Hirasawa A, Tsujimoto G, et al. (2007) The regulation of adipogenesis through GPR120. Biochem Biophys Res Commun 354:591-597.
14. Hansen SV and Ulven T (2017) Pharmacological Tool Compounds for the Free Fatty Acid Receptor 4 (FFA4/GPR120). Handb Exp Pharmacol 236:33-56.
15. Hasan AU, Ohmori K, Konishi K, Igarashi J, Hashimoto T, Kamitori K, Yamaguchi F, Tsukamoto I, Uyama T, Ishihara Y, et al. (2015) Eicosapentaenoic acid upregulates VEGF-A through both GPR120 and PPARg mediated pathways in 3T3-L1 adipocytes. Mol Cell Endocrinol 406:10-18.
16. Hashimoto Y, Kobayashi M, Matsuzaki E, Higashi K, Takahashi-Yanaga F, Takano A, Hirata M, and Nishimura F (2016) Sphingosine-1-phosphateenhanced Wnt5a promotes osteogenic differentiation in C3H10T1/2 cells. Cell Biol Int 40:1129-1136.
17. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, and Tsujimoto G (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11:90-94.
18. Houthuijzen JM (2016) For better or worse: FFAR1 and FFAR4 signaling in cancer and diabetes. Mol Pharmacol 90:738-743.
19. Houthuijzen JM, Oosterom I, Hudson BD, Hirasawa A, Daenen LG, McLean CM, Hansen SV, van Jaarsveld MT, Peeper DS, Jafari Sadatmand S, Roodhart JM, van de Lest CH, Ulven T, Ishihara K, Milligan G, Voest EE. (2017) Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance. FASEB J DOI: 10.1096/fj.201601248R [published ahead of print].
20. Hudson BD, Christiansen E, Murdoch H, Jenkins L, Hansen AH, Madsen O, Ulven T, and Milligan G (2014) Complex pharmacology of novel allosteric free fatty acid 3 receptor ligands. Mol Pharmacol 86:200-210.
21. Hudson BD, Shimpukade B, Mackenzie AE, Butcher AJ, Pediani JD, Christiansen E, Heathcote H, Tobin AB, Ulven T, and Milligan G (2013) The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol Pharmacol 84:710-725.
22. Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, Yengo L, Kimura I, Leloire A, Liu N, Iida K, et al. (2012) Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483:350-354.
23. Lee MN, Kim JW, Oh SH, Jeong BC, Hwang YC, and Koh JT (2016) FGF2 stimulates COUP-TFII expression via the MEK1/2 pathway to inhibit osteoblast differentiation in C3H10T1/2 cells. PLoS One 11:e0159234.
24. Li Z, Qiu Q, Geng X, Yang J, Huang W, and Qian H (2016) Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Expert Opin Investig Drugs 25:871-890.
25. Liu HD, Wang WB, Xu ZG, Liu CH, He DF, Du LP, Li MY, Yu X, and Sun JP (2015) FFA4 receptor (GPR120): A hot target for the development of anti-diabetic therapies. Eur J Pharmacol 763:160-168.
26. Liu Y, Guan X, Wong EL-M, Liu P, Huang J-S, and Che C-M (2013) Nonheme ironmediated amination of C(sp3)-H bonds. Quinquepyridine-supported iron-imide/ nitrene intermediates by experimental studies and DFT calculations. J Am Chem Soc 135:7194-7204.
27. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
28. Milligan G, Alvarez-Curto E, Watterson KR, Ulven T, and Hudson BD (2015) Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. Br J Pharmacol 172:3254-3265.
29. Milligan G, Shimpukade B, Ulven T, and Hudson BD (2017) Complex Pharmacology of Free Fatty Acid Receptors. Chem Rev 117:67-110.
30. Mo XL, Wei HK, Peng J, and Tao YX (2013) Free fatty acid receptor GPR120 and pathogenesis of obesity and type 2 diabetes mellitus. Prog Mol Biol Transl Sci 114: 251-276.
31. Mohammad S (2016) GPR40 agonists for the treatment of type 2 diabetes mellitus: benefits and challenges. Curr Drug Targets 17:1292-1300.
32. Moniri NH (2016) Free-fatty acid receptor-4 (GPR120): Cellular and molecular function and its role in metabolic disorders. Biochem Pharmacol 110-111:1-15.
33. Moran BM, Flatt PR, and McKillop AM (2016) G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis. Acta Diabetol 53:177-188.
34. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, and Olefsky JM (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687-698.
35. Oh DY, Walenta E, Akiyama TE, Lagakos WS, Lackey D, Pessentheiner AR, Sasik R, Hah N, Chi TJ, Cox JM, et al. (2014) A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med 20:942-947.
36. Patrick TB and Dolan JG (1973) Nitrosation of 9-acylamidoxanthines. J Org Chem 38:2828-2830.
37. Prihandoko R, Alvarez-Curto E, Hudson BD, Butcher AJ, Ulven T, Miller AM, Tobin AB, and Milligan G (2016) Distinct phosphorylation clusters determine the signaling outcome of free fatty acid receptor 4/G Protein-Coupled Receptor 120. Mol Pharmacol 89:505-520.
38. Quesada-López T, Cereijo R, Turatsinze JV, Planavila A, Cairó M, Gavaldà-Navarro A, Peyrou M, Moure R, Iglesias R, Giralt M, et al. (2016) The lipid sensor GPR120 promotes brown fat activation and FGF21 release from adipocytes. Nat Commun 7: 13479.
39. Shimpukade B, Hudson BD, Hovgaard CK, Milligan G, and Ulven T (2012) Discovery of a potent and selective GPR120 agonist. J Med Chem 55:4511-4515.
40. Song T, Zhou Y, Peng J, Tao YX, Yang Y, Xu T, Peng J, Ren J, Xiang Q, and Wei H (2016) GPR120 promotes adipogenesis through intracellular calcium and extracellular signal-regulated kinase 1/2 signal pathway. Mol Cell Endocrinol 434:1-13.
41. Sparks SM, Chen G, Collins JL, Danger D, Dock ST, Jayawickreme C, Jenkinson S, Laudeman C, Leesnitzer MA, Liang X, et al. (2014) Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg Med Chem Lett 24: 3100-3103.
42. Tamura Y, Nishikawa Y, Sumoto K, Ikeda M, Murase M, and Kise M (1977) Organic sulfur compounds. 5. Synthesis and rearrangement of thioxanthene N-(p-tolylsulfonyl)sulfilimine. J Org Chem 42:3226-3229.
43. Tang QQ, Otto TC, and Lane MD (2004) Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc Natl Acad Sci USA 101:9607-9611.
44. Ulven T and Christiansen E (2015) Dietary fatty acids and their potential for controlling metabolic diseases through activation of FFA4/GPR120. Annu Rev Nutr 35: 239-263.
45. Villegas-Comonfort S, Takei Y, Tsujimoto G, Hirasawa A, and García-Sáinz JA (2017) Effects of arachidonic acid on FFA4 receptor: Signaling, phosphorylation and internalization. Prostaglandins Leukot Essent Fatty Acids 117:1-10.
46. Watterson KR, Hudson BD, Ulven T, and Milligan G (2014) Treatment of type 2 diabetes by free Fatty Acid receptor agonists. Front Endocrinol (Lausanne) 5:137.
47. Wood MR, Hopkins CR, Brogan JT, Conn PJ, and Lindsley CW (2011) "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry 50:2403-2410.
48. Xu J, Li Z, Hou Y, and Fang W (2015) Potential mechanisms underlying the Runx2 induced osteogenesis of bone marrow mesenchymal stem cells. Am J Transl Res 7: 2527-2535.
49. Yuan Z, Li Q, Luo S, Liu Z, Luo D, Zhang B, Zhang D, Rao P, and Xiao J (2016) PPARg and Wnt signaling in adipogenic and osteogenic differentiation of mesenchymal stem cells. Curr Stem Cell Res Ther 11:216-225.
50. Zhang D and Leung PS (2014) Potential roles of GPR120 and its agonists in the management of diabetes. Drug Des Devel Ther 8:1013-1027.